In Vivo Treatments with Fulvestrant and Anastrozole Differentially Affect Gene Expression in the Rat Efferent Ductules

• Published in: Biology of reproduction 2011, Vol.84 (1), p.52-61
• Main Authors: Gomes, Gisele Renata Oliveira, Yasuhara, Fabiana, Siu, Erica Rosanna, Fernandes, Sheilla Alessandra Ferreira, Avellar, Maria Christina Werneck, Lazari, Maria Fatima Magalhaes, Porto, Catarina Segreti
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents, Hormonal - pharmacology; Biological and medical sciences; Ejaculatory Ducts - drug effects; Ejaculatory Ducts - metabolism; Estradiol - analogs & derivatives; Estradiol - blood; Estradiol - pharmacology; Fundamental and applied biological sciences. Psychology; Gene Expression Regulation - drug effects; Male; Nitriles - pharmacology; Rats; Rats, Wistar; Sp1 Transcription Factor - genetics; Sp1 Transcription Factor - metabolism; Testosterone - blood; Transcription Factor AP-1 - genetics; Transcription Factor AP-1 - metabolism; Triazoles - pharmacology; Vertebrates: reproduction
• ISSN: 0006-3363; 1529-7268
• DOI: 10.1095/biolreprod.110.085340

Estrogen plays a key role in maintaining the morphology and function of the efferent ductules. We previously demonstrated that the antiestrogen fulvestrant markedly affected gene expression in the rat efferent ductules. The mechanism of fulvestrant action to modulate gene expression may involve not only the blockade of ESR1 and ESR2 estrogen receptors, but also the activation of ESR1 and ESR2 when the receptors are tethered to AP-1 or SP1 transcription factors, or the activation of the G protein-coupled estrogen receptor 1. We therefore compared the effects of two strategies to interfere with estrogen action in the rat efferent ductules: treatment with fulvestrant or with the aromatase inhibitor anastrozole. Whereas fulvestrant markedly increased Mmp7 and Spp1, and reduced Nptx1 mRNA levels, no changes were observed with anastrozole. Fulvestrant caused changes in epithelial morphology that were not seen with anastrozole. Fulvestrant shifted MMP7 immunolocalization in the epithelial cells from the supranuclear to the apical region; this effect was less pronounced with anastrozole. In vitro studies of ³⁵S-methionine incorporation showed that protein release was increased, whereas tissue protein content in the efferent ductules of fulvestrant-treated rats was decreased. Although fulvestrant markedly affected gene expression, no changes were observed on AP-1 and SP1 DNA-binding activity. The blockade of ESRs seems to be the major reason explaining the differences between both treatments. At least some of the effects of fulvestrant appear to result from compensatory mechanisms activated by the dramatic changes caused by ESR1 blockade.